What you should know about the new Alzheimer’s drug

An older man rests his chin on his cane while sitting down at a table

In a highly anticipated announcement, the US Food and Drug Administration last week approved the first new drug for Alzheimer’s disease in nearly two decades.

That approval was not without controversy. Both before and after the FDA’s decision, physicians and researchers expressed a wide variety of perspectives on the drug’s potential, given a limited evidence base, and multiple stops and starts in its development and approval process.

The Alzheimer’s drug, called aducanumab during development and clinical trials, will be branded and sold as Aduhelm.

“I really believe this kicks off a new era in the fight against Alzheimer’s disease,” says Stephen Salloway, professor of neurology and psychiatry at Brown University who has been closely involved with the drug’s clinical development since the beginning.

Salloway directs the Memory and Aging Program at Butler Hospital and has been researching Alzheimer’s disease for 30 years.


 Get The Latest By Email

Weekly Magazine Daily Inspiration

He was a site principal investigator at Butler for both Phase 1 and Phase 3 trials of aducanumab, co-chair of the investigative steering committee for the Phase 3 program, and has advised the drug’s manufacturer, Biogen, on safety protocols and side effect management.

Here, he explains the key takeaways from the FDA’s headline-making decision and what it means for Alzheimer’s patients and for future research of the disease:

About The Author

Corrie Pikul-Brown

books_health

This article originally appeared on Futurity

AVAILABLE LANGUAGES

English Afrikaans Arabic Chinese (Simplified) Chinese (Traditional) Danish Dutch Filipino Finnish French German Greek Hebrew Hindi Hungarian Indonesian Italian Japanese Korean Malay Norwegian Persian Polish Portuguese Romanian Russian Spanish Swahili Swedish Thai Turkish Ukrainian Urdu Vietnamese

follow InnerSelf on

facebook icontwitter iconyoutube iconinstagram iconpintrest iconrss icon

 Get The Latest By Email

Weekly Magazine Daily Inspiration

Wednesday, 12 May 2021 08:30

In 2019, Burger King Sweden released a plant-based burger, the Rebel Whopper, and the reaction was underwhelming. So, the company challenged its customers to taste the difference.

Friday, 14 May 2021 08:30

Fertility has declined in most industrialised countries. While the causes are largely unknown, a number of factors may contribute to declining fertility rates, including the age...

Wednesday, 05 May 2021 08:15

While our immune system and antibiotics both do a great job of helping us fight life-threatening infections, the emergence of antibiotic resistance is quickly making it more difficult to cure...

Monday, 24 May 2021 08:28

There are many valid theories to explain the global appeal of cats, including our obsession with watching videos of them online. In terms of cats’ pure entertainment value, however, our...

Wednesday, 26 July 2023 12:55

With the rising cost of living, gyms memberships and fitness classes are becoming increasingly unaffordable. But the good news is you can make just as much progress at home.

Monday, 17 May 2021 08:55

Maybe you’re trying to eat healthier these days, aiming to get enough of the good stuff and limit the less-good stuff. You’re paying attention to things like fiber and fat and vitamins… and...

New Attitudes - New Possibilities

InnerSelf.comClimateImpactNews.com | InnerPower.net
MightyNatural.com | WholisticPolitics.com | InnerSelf Market
Copyright ©1985 - 2021 InnerSelf Publications. All Rights Reserved.